DK1592793T3 - Oligomeriske forbindelser for modulation af Survivin ekspression - Google Patents

Oligomeriske forbindelser for modulation af Survivin ekspression

Info

Publication number
DK1592793T3
DK1592793T3 DK04709580T DK04709580T DK1592793T3 DK 1592793 T3 DK1592793 T3 DK 1592793T3 DK 04709580 T DK04709580 T DK 04709580T DK 04709580 T DK04709580 T DK 04709580T DK 1592793 T3 DK1592793 T3 DK 1592793T3
Authority
DK
Denmark
Prior art keywords
modulation
oligomeric compounds
survivin expression
survivin
expression
Prior art date
Application number
DK04709580T
Other languages
English (en)
Inventor
Majken Westergaard
Margit Wissenbach
Jens Bo Rode Hansen
Charlotte Albaek Thrue
Kamille Dumong Petersen
Original Assignee
Santaris Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32852145&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1592793(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Santaris Pharma As filed Critical Santaris Pharma As
Application granted granted Critical
Publication of DK1592793T3 publication Critical patent/DK1592793T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
DK04709580T 2003-02-10 2004-02-10 Oligomeriske forbindelser for modulation af Survivin ekspression DK1592793T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200300183 2003-02-10
DKPA200301708 2003-11-18
PCT/DK2004/000096 WO2004069991A2 (en) 2003-02-10 2004-02-10 Oligomeric compounds for the modulation of survivin expression

Publications (1)

Publication Number Publication Date
DK1592793T3 true DK1592793T3 (da) 2009-10-26

Family

ID=32852145

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04709580T DK1592793T3 (da) 2003-02-10 2004-02-10 Oligomeriske forbindelser for modulation af Survivin ekspression

Country Status (10)

Country Link
EP (1) EP1592793B2 (da)
JP (3) JP4503590B2 (da)
AU (1) AU2004209598B2 (da)
CA (1) CA2515623A1 (da)
DE (1) DE602004022020D1 (da)
DK (1) DK1592793T3 (da)
ES (1) ES2329131T3 (da)
MX (1) MXPA05008319A (da)
PT (1) PT1592793E (da)
WO (1) WO2004069991A2 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003225495B2 (en) 2002-04-05 2009-01-15 Roche Innovation Center Copenhagen A/S Oligomeric compounds for the modulation HIF-1alpha expression
DK1569661T3 (da) 2002-11-18 2010-01-11 Santaris Pharma As Antisense design
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
EP1592793B2 (en) * 2003-02-10 2014-05-07 Santaris Pharma A/S Oligomeric compounds for the modulation of survivin expression
ATE401088T1 (de) * 2004-04-22 2008-08-15 Lilly Co Eli Zusammensetzung mit einem survivin-antisense- oligonucleotid und gemcitabin zur behandlung von krebs
DE602005023772D1 (de) * 2004-11-09 2010-11-04 Santaris Pharma As Lna-oligonukleotide und krebsbehandlung
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
KR20070095882A (ko) 2004-11-09 2007-10-01 산타리스 팔마 에이/에스 Ｌｎａ 올리고뉴클레오티드 및 암의 치료
ATE476441T1 (de) 2004-11-09 2010-08-15 Santaris Pharma As Wirksame lna-oligonukleotide zur inhibierung von hif-1a
SG10201406016SA (en) 2006-04-03 2014-11-27 Stella Aps Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
CA2649045C (en) 2006-04-03 2019-06-11 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
JP5665317B2 (ja) 2006-10-18 2015-02-04 アイシス ファーマシューティカルズ， インコーポレーテッド アンチセンス化合物
WO2008113832A2 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
CA2681406A1 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S Rna antagonist compounds for the inhibition of apo-b100 expression
EP3492594A1 (en) 2007-10-04 2019-06-05 Roche Innovation Center Copenhagen A/S Micromirs
JP2009171895A (ja) * 2008-01-24 2009-08-06 Hitachi Software Eng Co Ltd 核内ノンコーディングｒｎａの機能解析方法
AU2009221064B2 (en) 2008-03-07 2014-12-11 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of microRNA related diseases
WO2010012667A1 (en) 2008-08-01 2010-02-04 Santaris Pharma A/S Micro-rna mediated modulation of colony stimulating factors
US20110236972A1 (en) * 2008-08-05 2011-09-29 Marina Biotech, Inc. Nucleic acid compounds for inhibiting birc5 gene expression and uses thereof
ES2599979T3 (es) 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
EP3467109A1 (en) 2011-02-08 2019-04-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
DE102011100581A1 (de) * 2011-05-04 2012-11-08 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von hyperproliferativen Erkrankungen des Urogenitaltraktes
WO2013022966A1 (en) 2011-08-11 2013-02-14 Isis Pharmaceuticals, Inc. Linkage modified gapped oligomeric compounds and uses thereof
WO2013159108A2 (en) 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
WO2014059353A2 (en) 2012-10-11 2014-04-17 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleosides and uses thereof
JP6472087B2 (ja) * 2013-05-30 2019-02-27 国立大学法人 東京医科歯科大学 治療用オリゴヌクレオチドを送達するための二本鎖剤
ES2770667T3 (es) 2013-06-27 2020-07-02 Roche Innovation Ct Copenhagen As Oligómeros antisentido y conjugados que se dirigen a PCSK9
JP6429264B2 (ja) * 2013-11-12 2018-11-28 学校法人東京理科大学 ボラノホスフェート化合物、及び核酸オリゴマー
US11326210B2 (en) * 2015-01-30 2022-05-10 Glax Llc Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer
US20190055550A1 (en) * 2015-08-24 2019-02-21 Roche Innovation Center Copenhagen A/S LNA-G Process
WO2017078099A1 (ja) * 2015-11-06 2017-05-11 東レ株式会社 癌の治療及び／又は予防用医薬組成物
KR101841350B1 (ko) * 2016-07-05 2018-03-22 한양대학교 산학협력단 이중 플라스미드 벡터를 포함하는 지방세포 표적 비바이러스성 유전자 전달 복합체
EP3491001A1 (en) 2016-07-27 2019-06-05 Roche Innovation Center Copenhagen A/S 5's-lna nucleotides and oligonucleotides
US20190284581A1 (en) * 2016-08-12 2019-09-19 Nexuspiral Inc. Genome editing method
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
AU2019316103A1 (en) 2018-08-02 2021-03-11 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11931421B2 (en) 2022-04-15 2024-03-19 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
US20240182561A1 (en) 2022-11-04 2024-06-06 Regeneron Pharmaceuticals, Inc. Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
WO2024107765A2 (en) 2022-11-14 2024-05-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248670A (en) † 1990-02-26 1993-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides for inhibiting herpesviruses
EP1557424A1 (en) 1997-09-12 2005-07-27 Exiqon A/S Bi-cyclic nucleoside, nucleotide and oligonucleoide analogues
US6838283B2 (en) * 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
WO2000025248A2 (en) 1998-10-26 2000-05-04 Intervu, Inc. Audience management for interactive network events
KR20020013513A (ko) 1999-03-18 2002-02-20 추후제출 Ｘｙｌｏ-ｌｎａ 유사체
US6639059B1 (en) 1999-03-24 2003-10-28 Exiqon A/S Synthesis of [2.2.1]bicyclo nucleosides
NZ514348A (en) 1999-05-04 2004-05-28 Exiqon As L-ribo-LNA analogues
IL149694A0 (en) * 1999-12-23 2002-11-10 Exiqon As Therapeutic uses of lna-modified oligonucleotides
DE60119562T2 (de) 2000-10-04 2007-05-10 Santaris Pharma A/S Verbesserte synthese von purin-blockierten nukleinsäure-analoga
AU2002317437A1 (en) * 2001-05-18 2002-12-03 Cureon A/S Therapeutic uses of lna-modified oligonucleotides in infectious diseases
EP1409497B1 (en) 2001-07-12 2005-01-19 Santaris Pharma A/S Method for preparation of lna phosphoramidites
US20030224515A1 (en) † 2002-06-04 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of sterol regulatory element-binding protein-1 expression
US20040005567A1 (en) † 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of cyclin-dependent kinase 4 expression
WO2003091384A2 (en) * 2002-04-24 2003-11-06 Eirx Therapeutics Limited A role for survivin in apoptosis of myeloid cells
EP1592793B2 (en) * 2003-02-10 2014-05-07 Santaris Pharma A/S Oligomeric compounds for the modulation of survivin expression

Also Published As

Publication number Publication date
EP1592793B1 (en) 2009-07-15
JP4503590B2 (ja) 2010-07-14
PT1592793E (pt) 2009-09-30
AU2004209598A1 (en) 2004-08-19
JP2013066471A (ja) 2013-04-18
DE602004022020D1 (de) 2009-08-27
EP1592793A2 (en) 2005-11-09
EP1592793B2 (en) 2014-05-07
ES2329131T3 (es) 2009-11-23
CA2515623A1 (en) 2004-08-19
MXPA05008319A (es) 2006-02-28
JP2010178742A (ja) 2010-08-19
JP2007523601A (ja) 2007-08-23
AU2004209598B2 (en) 2009-08-06
WO2004069991A2 (en) 2004-08-19
WO2004069991A3 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
DK1592793T3 (da) Oligomeriske forbindelser for modulation af Survivin ekspression
DK2264172T3 (da) Oligomerforbindelser til modulering af HIF-1á-ekspression
HK1108454A1 (en) Modulation of survivin expression
SE0302305D0 (sv) Novel Compounds
IS8348A (is) Samrunnin heteróhringasambönd
DK1778618T3 (da) Syntese af triethylentetraminer
DK2377869T3 (da) Syntese af Bortezomib
IS8108A (is) Ný efnasambönd
DK1633697T3 (da) Fremgangsmåde til fremstilling af substituerede 3-aryl-butyl-aminforbindelser
DK1476162T3 (da) Kontrolleret syntese af ziprasidone
AU2003300020A8 (en) Modulation of pten expression via oligomeric compounds
DK1716119T3 (da) Analoger af benzoquinonholdige ansamyciner til behandling af cancer
IS8228A (is) Ný asetídínefnasambönd
DK1713801T3 (da) Fremgangsmåde til fremstilling af 1-(2S,3S)-2-benzhydryl-N-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amin
DK1840125T3 (da) Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater
DK1512324T3 (da) Fremgangsmåde til dearomatisering af materialer stammende fra soja
DK1516540T3 (da) Anvendelse af vitamin D-forbindelser
DK1353923T3 (da) Forbedret fremgangsmåde til syntese af carbapenem
DK1578731T3 (da) Fremgangsmåde til fremstilling af pyrimidinforbindelser
DK1645165T3 (da) Modtagerenhed til reducering af tilbagekobling
DK1678135T3 (da) Fremgangsm de til fremstilling af n-amino-substituerede hetorocykliske forbindelser
DK1575941T3 (da) Fremgangsmåde til fremstilling af (S)-pantoprazol
DK1597366T3 (da) Modulering af ekspression af insulin-lignende vækstfaktor receptor I
DK1667975T3 (da) En polymorf form for 3-phenylsulfonyl-8-piperazin-1-yl-quinolin
DK1656365T3 (da) Fremgangsmåde til fremstilling af enantiomerisk rent mirtazapin